Prescription medication · Conjugated Estrogen
conjugated estrogens
Also sold as Premarin. Premarin Intravenous treats unusual bleeding from the uterus when it's caused by hormone problems and not by other health issues.
Data updated 2026-05-15
- 57,675
- FDA reportsOften reported
- 1
- InteractionFew interactions
- $6.62
- Brand price (NADAC)
What the data shows
conjugated estrogens (Premarin) is a prescription Conjugated Estrogen, more reported than most tracked drugs (57,675 FDA reports), with 1 documented drug interaction.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
conjugated estrogens (Premarin) is a prescription Conjugated Estrogen. Premarin Intravenous treats unusual bleeding from the uterus when it's caused by hormone problems and not by other health issues.
Premarin Intravenous is an injectable medicine that contains estrogen hormones. It is used to quickly raise estrogen levels for a short time.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$6.62/unit
Generic Available
No
WYETH PHARMS
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Premarin Intravenous treats unusual bleeding from the uterus when it's caused by hormone problems and not by other health issues.
Common side effects
Nausea, Headache, Dizziness
Key warnings
Estrogen-alone therapy can increase the risk of uterine cancer, stroke, blood clots, and dementia.
The sections below are summarized in plain English from conjugated estrogens's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Premarin Intravenous contains estrogen hormones. These hormones help to control the menstrual cycle. By providing estrogen, it can help stop abnormal uterine bleeding caused by a hormone imbalance.
Side Effects (from patient reports)
Based on 57,675 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for conjugated estrogens, by number of reports
- Breast Cancer
Breast Cancer
9,623 reports
- Breast Cancer Female
Breast Cancer Female
8,862 reports
- Nausea 2,360
Nausea
2,360 reports
- Headache 2,291
Headache
2,291 reports
- Pain 2,248
Pain
2,248 reports
- Fatigue 2,198
Fatigue
2,198 reports
- Breast Cancer Metastatic 1,681
Breast Cancer Metastatic
1,681 reports
- Dizziness 1,632
Dizziness
1,632 reports
- Dyspnoea 1,614
Dyspnoea
1,614 reports
- Malaise 1,573
Malaise
1,573 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for conjugated estrogens each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where conjugated estrogens sits
conjugated estrogens has more FDA adverse-event reports than 76% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is conjugated estrogens; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 57,675 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 1996–2025.
Total Reports
57,675
Reports Mentioning Death
1,777
3.1% of reports — not proof of cause
Hospitalization Reports
9,226
Top Indication
Hormone Replacement Therapy
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | BREAST CANCER | 9,623 |
| 2 | BREAST CANCER FEMALE | 8,862 |
| 4 | NAUSEA | 2,360 |
| 5 | HEADACHE | 2,291 |
| 6 | PAIN | 2,248 |
| 7 | FATIGUE | 2,198 |
| 9 | BREAST CANCER METASTATIC | 1,681 |
| 10 | DIZZINESS | 1,632 |
| 11 | DYSPNOEA | 1,614 |
| 12 | MALAISE | 1,573 |
| 13 | DIARRHOEA | 1,521 |
| 14 | ARTHRALGIA | 1,438 |
| 15 | ANXIETY | 1,421 |
| 16 | DEPRESSION | 1,402 |
| 17 | INSOMNIA | 1,287 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Estrogen-alone therapy can increase the risk of uterine cancer, stroke, blood clots, and dementia. Estrogen with progestin can increase the risk of blood clots, stroke, heart attack, and dementia. Use the lowest dose for the shortest time needed.
Known Drug Interactions
Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] .
Mechanism: Itraconazole slows down how your body processes this medication, which can cause the levels of the drug in your blood to rise.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What is Premarin Intravenous used for?
How is Premarin Intravenous given?
Can I use Premarin Intravenous if I have breast cancer?
What should I do if I experience side effects?
Can I use Premarin Intravenous if I am pregnant?
How often will I receive the injection?
Does Premarin Intravenous prevent heart disease or dementia?
What should I tell my doctor before using Premarin Intravenous?
Can Premarin Intravenous cause blood clots?
How should I store Premarin Intravenous before it is mixed?
What are the common side effects of conjugated estrogens?
Does conjugated estrogens interact with other medications?
What drug class is conjugated estrogens?
What pregnancy or breastfeeding source fields are listed for conjugated estrogens?
Related Medications in Conjugated Estrogen
Other drugs grouped near conjugated estrogens - same-class peers and common alternatives.
abiraterone
Zytiga
Abiraterone (Zytiga) is a medicine used with prednisone to treat prostate cancer that has spread.
Compare with conjugated estrogens →
anastrozole
Arimidex
Anastrozole is a medicine used to treat breast cancer in women after menopause.
Compare with conjugated estrogens →
bazedoxifene/conjugated estrogens
Duavee
Duavee is a combination medicine containing estrogen and a drug that blocks estrogen in some parts of the body.
Compare with conjugated estrogens →
cabergoline
Dostinex
Cabergoline is a medicine that helps lower the amount of prolactin in your body.
Compare with conjugated estrogens →
clomiphene
Clomid, Serophene
Clomiphene citrate is a medicine that helps women ovulate.
Compare with conjugated estrogens →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for conjugated estrogens: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 57,675.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 3.08%.
- guanfacine Δ 0.01 pts · 7,386 reports · Central Alpha-2 Agonist 3.09%death share
- biotin Δ 0.03 pts · 29,879 reports · Vitamin B7 Supplement 3.05%death share
- netarsudil Δ 0.04 pts · 1,797 reports · Rho Kinase Inhibitor (Ophthalmic) 3.12%death share
- azelastine Δ 0.05 pts · 16,672 reports · Antihistamine (Nasal) 3.13%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on conjugated estrogens
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for conjugated estrogens
The FDA label for conjugated estrogens (sold under brand names such as Premarin) classifies it as a prescription-only medication in the Conjugated Estrogen class. Premarin Intravenous treats unusual bleeding from the uterus when it's caused by hormone problems and not by other health issues. Official labeling lists 8 commonly reported side effects, including Nausea, Headache, Dizziness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 57,675 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: May 30, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages